Altered Mitochondrial Function, Mitochondrial DNA and Reduced Metabolic Flexibility in Patients With Diabetic Nephropathy

EBioMedicine

Volumn 2, Issue 6, 2015, Pages 499-512

  Czajka, Anna ^a   Ajaz, Saima ^a   Gnudi, Luigi ^b   Parsade, Chandani Kiran ^a   Jones, Peter ^a   Reid, Fiona ^c   Malik, Afshan N ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Cardiovascular Division   (United Kingdom)

^c Department of Primary Care and Public Health Sciences ^*  (United Kingdom)

Author keywords

Bioenergetic deficit; Bioenergetic health index (BHI); Diabetic nephropathy; Hyperglycemia; Mitochondrial DNA; Mitochondrial dysfunction

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALBUMIN; CHOLESTEROL; CREATININE; CYTOCHROME C OXIDASE; DYNAMIN 1 LIKE PROTEIN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MITOFUSIN 1; MITOFUSIN 2; MYELOID DIFFERENTIATION FACTOR 88; OPTIC ATROPHY 1 PROTEIN; PARKIN RBR E3 UBIQUITIN PROTEIN LIGASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN; PTEN INDUCED PUTATIVE KINASE 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; TLR9 PROTEIN, HUMAN;

ADULT; AGE; APOPTOSIS; ARTICLE; ASSESSMENT OF HUMANS; BIOENERGETIC HEALTH INDEX; BIOENERGY; BODY MASS; CELL VIABILITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MESANGIUM CELL; METABOLIC FLUX ANALYSIS; MIDDLE AGED; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL RESPIRATION; MITOPHAGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; BLOOD; CELL CULTURE; DIABETES MELLITUS; ENERGY METABOLISM; ENZYME ACTIVATION; GENETICS; METABOLISM; MITOCHONDRION; MONONUCLEAR CELL; PATHOLOGY; PHYSIOLOGY;

CELLS, CULTURED; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DNA, MITOCHONDRIAL; ENERGY METABOLISM; ENZYME ACTIVATION; GLUCOSE; HUMANS; HYPERGLYCEMIA; LEUKOCYTES, MONONUCLEAR; MESANGIAL CELLS; MITOCHONDRIA; MITOCHONDRIAL DEGRADATION; TOLL-LIKE RECEPTOR 9;

EID: 84947602703     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.04.002     Document Type: Article

References (68)

1. Aguer C., Pasqua M., Thrush A.B., Moffat C., McBurney M., Jardine K., Zhang R., Beauchamp B., Dent R., McPherson R., et al. Increased proton leak and SOD2 expression in myotubes from obese non-diabetic subjects with a family history of type 2 diabetes. Biochim. Biophys. Acta 2013, 1832:1624-1633.
2. Ajaz S., Czajka A., Malik A.N. Accurate measurement of circulating mitochondrial DNA content from human blood samples using real-time quantitative PCR. Methods Mol. Biol. 2014, 1264.
3. Alaveras A.E., Thomas S.M., Sagriotis A., Viberti G.C. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Nephrol. Dial. Transplant. 1997, 12(Suppl. 2):71-74.
4. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv. Cardiol. 2008, 45:1-16.
5. Ballinger S.W., Patterson C., Yan C.N., Doan R., Burow D.L., Young C.G., Yakes F.M., Van Houten B., Ballinger C.A., Freeman B.A., et al. Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ. Res. 2000, 86:960-966.
6. Bannwarth S., Procaccio V., Paquis-Flucklinger V. Rapid identification of unknown heteroplasmic mutations across the entire human mitochondrial genome with mismatch-specific Surveyor Nuclease. Nat. Protoc. 2006, 1:2037-2047.
7. Brand M.D., Nicholls D.G. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011, 435:297-312.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
9. -(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem. J. 2010, 432:9-19.
10. Chacko B.K., Reily C., Benavides C.A., Johnson M.S., Darley-Usmar A.V.M. Chronic Hyperglycemia-induced Attenuation of Mitochondrial Reserve Capacity Mediates Mesangial Cell Dysfunction in Diabetes 2010.
11. Chacko B.K., Kramer P.A., Ravi S., Johnson M.S., Hardy R.W., Ballinger S.W., Darley-Usmar V.M. Methods for defining distinct bioenergetic profiles in platelets, lymphocytes, monocytes, and neutrophils, and the oxidative burst from human blood. Lab. Investig. 2013, 93:690-700.
12. Chacko B.K., Kramer P.A., Ravi S., Benavides G.A., Mitchell T., Dranka B.P., Ferrick D., Singal A.K., Ballinger S.W., Bailey S.M., et al. The Bioenergetic Health Index: a new concept in mitochondrial translational research. Clin. Sci. (Lond.) 2014, 127:367-373.
13. Chinnery P.F. Modulating heteroplasmy. Trends Genet. 2002, 18:173-176.
14. Choi Y.S., Lee K.U., Pak Y.K. Regulation of mitochondrial transcription factor A expression by high glucose. Ann. N. Y. Acad. Sci. 2004, 1011:69-77.
15. Clarkson M.R., Murphy M., Gupta S., Lambe T., Mackenzie H.S., Godson C., Martin F., Brady H.R. High glucose-altered gene expression in mesangial cells. Actin-regulatory protein gene expression is triggered by oxidative stress and cytoskeletal disassembly. J. Biol. Chem. 2002, 277:9707-9712.
16. Collins L.V., Hajizadeh S., Holme E., Jonsson I.M., Tarkowski A. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J. Leukoc. Biol. 2004, 75:995-1000.
17. Colussi C., Albertini M.C., Coppola S., Rovidati S., Galli F., Ghibelli L. H2O2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells from apoptosis 2000.
18. D'Aco K.E., Manno M., Clarke C., Ganesh J., Meyers K.E., Sondheimer N. Mitochondrial tRNA(Phe) mutation as a cause of end-stage renal disease in childhood. Pediatr. Nephrol. 2013, 28:515-519.
19. Dranka B.P., Benavides G.A., Diers A.R., Giordano S., Zelickson B.R., Reily C., Zou L., Chatham J.C., Hill B.G., Zhang J., et al. Assessing bioenergetic function in response to oxidative stress by metabolic profiling. Free Radic. Biol. Med. 2011, 51:1621-1635.
20. Ferrick D.A., Neilson A., Beeson C. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov. Today 2008, 13:268-274.
21. Furda A., Santos J.H., Meyer J.N., Van Houten B. Quantitative PCR-based measurement of nuclear and mitochondrial DNA damage and repair in mammalian cells. Methods Mol. Biol. 2014, 1105:419-437.
22. Gordin D., Waden J., Forsblom C., Thorn L.M., Rosengard-Barlund M., Heikkila O., Saraheimo M., Tolonen N., Hietala K., Soro-Paavonen A., et al. Arterial stiffness and vascular complications in patients with type 1 diabetes: the Finnish Diabetic Nephropathy (FinnDiane) Study. Ann. Med. 2012, 44:196-204.
23. Gruden G., Thomas S., Burt D., Lane S., Chusney G., Sacks S., Viberti G. Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:12112-12116.
24. Hartman M.L., Shirihai O.S., Holbrook M., Xu G., Kocherla M., Shah A., Fetterman J.L., Kluge M.A., Frame A.A., Hamburg N.M., et al. Relation of mitochondrial oxygen consumption in peripheral blood mononuclear cells to vascular function in type 2 diabetes mellitus. Vasc. Med. 2014, 19:67-74.
25. He Z., King G.L. Microvascular complications of diabetes. Endocrinol. Metab. Clin. N. Am. 2004, 33:215-238. (xi-xii).
26. Higginbotham J.N., Seth P., Blaese R.M., Ramsey W.J. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum. Gene Ther. 2002, 13:129-141.
27. Hock M.B., Kralli A. Transcriptional control of mitochondrial biogenesis and function. Annu. Rev. Physiol. 2009, 71:177-203.
28. Hofmann M.A., Schiekofer S., Isermann B., Kanitz M., Henkels M., Joswig M., Treusch A., Morcos M., Weiss T., Borcea V., et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia 1999, 42:222-232.
29. Hudson G., Gomez-Duran A., Wilson I.J., Chinnery P.F. Recent mitochondrial DNA mutations increase the risk of developing common late-onset human diseases. PLoS Genet. 2014, 10:e1004369.
30. IDF Diabetes Atlas 2013, International Diabetes Federation. 6th edition.
31. Ihm C.G., Park J.K., Hong S.P., Lee T.W., Cho B.S., Kim M.J. Circulating factors in sera or peripheral blood mononuclear cells in patients with membranous nephropathy or diabetic nephropathy. J. Korean Med. Sci. 1997, 12:539-544.
32. Kalyanaraman B., Darley-Usmar V., Davies K.J., Dennery P.A., Forman H.J., Grisham M.B., Mann G.E., Moore K., Roberts L.J., Ischiropoulos H. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic. Biol. Med. 2012, 52:1-6.
33. Kilpatrick E.S., Rigby A.S., Atkin S.L. The Diabetes Control and Complications Trial: the gift that keeps giving. Nat. Rev. Endocrinol. 2009, 5:537-545.
34. --mediated mitochondrial outgrowth. Am. J. Physiol. Cell Physiol. 2005, 288:C1440-C1450.
35. Lee H.C., Wei Y.H. Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int. J. Biochem. Cell Biol. 2005, 37:822-834.
36. Lee J.E., Park H., Ju Y.S., Kwak M., Kim J.I., Oh H.Y., Seo J.S. Higher mitochondrial DNA copy number is associated with lower prevalence of microalbuminuria. Exp. Mol. Med. 2009, 41:253-258.
37. Malik A.N., Czajka A. Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction?. Mitochondrion 2013, 13(5):481-492.
38. Malik A.N., Shahni R., Iqbal M.M. Increased peripheral blood mitochondrial DNA in type 2 diabetic patients with nephropathy. Diabetes Res. Clin. Pract. 2009, 86:e22-e24.
39. Malik A.N., Shahni R., Rodriguez-de-Ledesma A., Laftah A., Cunningham P. Mitochondrial DNA as a non-invasive biomarker: accurate quantification using real time quantitative PCR without co-amplification of pseudogenes and dilution bias. Biochem. Biophys. Res. Commun. 2011, 412:1-7.
40. Maynard S., Keijzers G., Gram M., Desler C., Bendix L., Budtz-Jorgensen E., Molbo D., Croteau D.L., Osler M., Stevnsner T., et al. Relationships between human vitality and mitochondrial respiratory parameters, reactive oxygen species production and dNTP levels in peripheral blood mononuclear cells. Aging (Albany NY) 2013, 5:850-864.
41. Mazzaccara C., Iafusco D., Liguori R., Ferrigno M., Galderisi A., Vitale D., Simonelli F., Landolfo P., Prisco F., Masullo M., et al. Mitochondrial diabetes in children: seek and you will find it. PLoS One 2012, 7:e34956.
42. Michel S., Wanet A., De Pauw A., Rommelaere G., Arnould T., Renard P. Crosstalk between mitochondrial (dys)function and mitochondrial abundance. J. Cell. Physiol. 2012, 227:2297-2310.
43. Moraes C.T., Shanske S., Tritschler H.J., Aprille J.R., Andreetta F., Bonilla E., Schon E.A., DiMauro S. mtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am. J. Hum. Genet. 1991, 48:492-501.
44. Murphy M., Godson C., Cannon S., Kato S., Mackenzie H.S., Martin F., Brady H.R. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J. Biol. Chem. 1999, 274:5830-5834.
45. Navarro-Gonzalez J.F., Mora-Fernandez C., Muros de Fuentes M., Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 2011, 7:327-340.
46. Niaudet P. Mitochondrial disorders and the kidney. Arch. Dis. Child. 1998, 78:387-390.
47. Oka T., Hikoso S., Yamaguchi O., Taneike M., Takeda T., Tamai T., Oyabu J., Murakawa T., Nakayama H., Nishida K., Akira S., Yamamoto A., Komuro I., Otsu K. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012, 485:251-255.
48. Ritz E., Orth S.R. Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med. 1999, 341:1127-1133.
49. Rudkowska I., Raymond C., Ponton A., Jacques H., Lavigne C., Holub B.J., Marette A., Vohl M.C. Validation of the use of peripheral blood mononuclear cells as surrogate model for skeletal muscle tissue in nutrigenomic studies. OMICS 2011, 15:1-7.
50. Seidowsky A., Hoffmann M., Glowacki F., Dhaenens C.M., Devaux J.P., de Sainte Foy C.L., Provot F., Gheerbrant J.D., Hummel A., Hazzan M., et al. Renal involvement in MELAS syndrome - a series of 5 cases and review of the literature. Clin. Nephrol. 2013, 80:456-463.
51. Shahni R., Czajka A., Mankoo B.S., Guvenel A.K., King A.J., Malik A.N. Nop-7-associated 2 (NSA2), a candidate gene for diabetic nephropathy, is involved in the TGFbeta1 pathway. Int. J. Biochem. Cell Biol. 2013, 45:626-635.
52. Sharma K., Karl B., Mathew A.V., Gangoiti J.A., Wassel C.L., Saito R., Pu M., Sharma S., You Y.H., Wang L., et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J. Am. Soc. Nephrol. 2013, 24:1901-1912.
53. Singh D.K., Winocour P., Farrington K. Oxidative stress in early diabetic nephropathy: fueling the fire. Nat. Rev. Endocrinol. 2011, 7:176-184.
54. Sobenin I.A., Mitrofanov K.Y., Zhelankin A.V., Sazonova M.A., Postnov A.Y., Revin V.V., Bobryshev Y.V., Orekhov A.N. Quantitative assessment of heteroplasmy of mitochondrial genome: perspectives in diagnostics and methodological pitfalls. BioMed Res. Int. 2014, 2014:292017.
55. Sourris K.C., Harcourt B.E., Penfold S.A., Yap F.Y., Morley A.L., Morgan P.E., Davies M.J., Baker S.T., Jerums G., Forbes J.M. Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy. Exp. Diabetes Res. 2010, 2010:974681.
56. Stoves J., Lindley E.J., Barnfield M.C., Burniston M.T., Newstead C.G. MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function. Nephrol. Dial. Transplant. 2002, 17:2036-2037.
57. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
58. Thomas S., Vanuystel J., Gruden G., Rodriguez V., Burt D., Gnudi L., Hartley B., Viberti G. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J. Am. Soc. Nephrol. 2000, 11:1236-1243.
59. Trudeau K., Molina A.J., Guo W., Roy S. High glucose disrupts mitochondrial morphology in retinal endothelial cells: implications for diabetic retinopathy. Am. J. Pathol. 2010, 177:447-455.
60. Tuppen H.A., Blakely E.L., Turnbull D.M., Taylor R.W. Mitochondrial DNA mutations and human disease. Biochim. Biophys. Acta 2010, 1797:113-128.
61. Wallace D.C. Mitochondrial diseases in man and mouse. Science 1999, 283:1482-1488.
62. Wallace D.C., Chalkia D. Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease. Cold Spring Harb. Perspect. Med. 2013, 3:a021220.
63. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
64. Williams R.S. Mitochondrial gene expression in mammalian striated muscle. Evidence that variation in gene dosage is the major regulatory event. J. Biol. Chem. 1986, 261:12390-12394.
65. Wojtczak L., Zabłocki K. Basic mitochondria physiology in cell viability and death. Drug-induced Mitochondria Dysfunction 2008, 3-36. John Wiley & Sons, Inc., New Jersey. J.A. Dykens, Y. Will (Eds.).
66. Ye K., Lu J., Ma F., Keinan A., Gu Z. Extensive pathogenicity of mitochondrial heteroplasmy in healthy human individuals. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:10654-10659.
67. Yi B., Hu X., Zhang H., Huang J., Liu J., Hu J., Li W., Huang L. Nuclear NF-kappaB p65 in peripheral blood mononuclear cells correlates with urinary MCP-1, RANTES and the severity of type 2 diabetic nephropathy. PLoS One 2014, 9:e99633.
68. Zhang Y., Lee A.S., Shameli A., Geng X., Finegood D., Santamaria P., Dutz J.P. TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes. J. Immunol. 2010, 184:5645-5653.